Volume 17, Issue 12, Pages 1672-1682 (December 2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study  Dr Daniel R Gomez, MD, Prof George R Blumenschein, MD, Prof J Jack Lee, PhD, Mike Hernandez, MS, Rong Ye, MS, Prof D Ross Camidge, MD, Robert C Doebele, MD, Ferdinandos Skoulidis, MD, Prof Laurie E Gaspar, MD, Don L Gibbons, MD, Jose A Karam, MD, Prof Brian D Kavanagh, MD, Chad Tang, MD, Prof Ritsuko Komaki, MD, Alexander V Louie, MD, David A Palma, MD, Anne S Tsao, MD, Boris Sepesi, MD, William N William, MD, Jianjun Zhang, MD, Qiuling Shi, PhD, Xin Shelley Wang, MD, Prof Stephen G Swisher, MD, Prof John V Heymach, MD  The Lancet Oncology  Volume 17, Issue 12, Pages 1672-1682 (December 2016) DOI: 10.1016/S1470-2045(16)30532-0 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile *Includes patients who developed a new lesion after their first progression event. The Lancet Oncology 2016 17, 1672-1682DOI: (10.1016/S1470-2045(16)30532-0) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 2 Progression-free survival (A) and time to appearance of disease at a new site (B) The Lancet Oncology 2016 17, 1672-1682DOI: (10.1016/S1470-2045(16)30532-0) Copyright © 2016 Elsevier Ltd Terms and Conditions